Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2018 / N 3

Роль β-адреноблокаторов в снижении симпатического тонуса у больных артериальной гипертонией
Ю.А. Карпов, А.Т. Шубина

Список литературы
1. Palatini P, Rosei EA, Casiglia E, Chalmers J, Ferrari R, Grassi G, Inoue T, Jelakovic B, Jensen MT, Julius S, Kjeldsen SE, Mancia G, Parati G, Pauletto P, Stella A, Zanchetti A. Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. Journal of Hypertension 2016 May;34(5):813-21.
2. Grassi G. Sympathetic overdrive in hypertension: clinical and therapeutic relevance. An article from the e-journal of the ESC Council for Cardiology Practice. 24 Nov 2015;13(36).
3. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circulation Research 2014 May;114(11):1804-14.
4. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circulation Research 2015 Mar;116(6):976-90.
5. Cruickshank JM. Diabetes and the younger/middle-aged hypertensive subject; obesity, sympathetic nerve activity and treatment implications. Journal of Diabetes Research and Therapy 2016 Nov;3(1).
6. Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. Journal of the American Society of Hypertension 2016 May;10(5):457-66.
7. Park CS, Lee HY. Clinical utility of sympathetic blockade in cardiovascular disease management. Expert Review of Cardiovascular Therapy 2017 Mar;15(4):277-88.
8. Шубина А.Т., Демидова И.Ю., Карпов Ю.А. Влияние метформина на суточный профиль артериального давления у больных с метаболическим синдромом Х. Международный журнал медицинской практики 2001;1:33-5.
9. Кобалава Ж.Д., Котовская Ю.В. Особенности суточного профиля артериального давления у больных гипертонической болезнью с метаболическими нарушениями. Клиническая фармакология и терапия 1995;4(3):50-1.
10. Neilsen FS, Hansen HP, Jacobsen P, Rossing P, Smidt UM, Christensen NJ, Pevet P, Vivien-Roels B, Parving HH. Increased sympathetic activity during sleep and nocturnal hypertension in type 2 diabetic patients with diabetic nephropathy. Diabetic Medicine 1999 Jul;16(7):555-62.
11. Farinaro E, Stranges S, Guglielmucci G, Iermano P, Celentano E, Cajafa A, Trevisan M. Heart rate as a risk factor in hypertensive individuals. The Italian TensioPulse Study. Nutrition, Metabolism and Cardiovascular Diseases 1999 Aug;9(4):196-202.
12. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahl@öf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. European Heart Journal 2010 Sep;31(18):2271-9.
13. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. The American Journal of Cardiology 2012 Mar;109(5):685-92.
14. Palatini P, Reboldi G, Beilin LJ, Eguchi K, Imai Y, Kario K, Ohkubo T, Pierdomenico SD, Saladini F, Schwartz JE, Wing L, Verdecchia P. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. International Journal of Cardiology 2013;168(2):1490-5.
15. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympatoadrenal system. The New England Journal of Medicine 1996 Feb;334(6):374-81.
16. Шубина А.Т., Демидова И.Ю., Карпов Ю.А. Метаболический синдром Х: предпосылки к развитию артериальной гипертонии и атеросклероза. Клиническая фармакология и терапия 2001;10(4):44-7.
17. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circulation Research 2015 Mar;116(6):976-90.
18. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Current Opinion in Nephrology and Hypertension 2012;21(1):46-51.
19. Карпов Ю.А., Шубина А.Т. Применение β-блокаторов в лечении больных артериальной гипертонией: новые возможности и перспективы. Русский медицинский журнал 2005;13(19):1265-9.
20. Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. Journal of Cardiovascular Pharmacology 1986;8(Suppl 11):S36-40.
21. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta1- and beta2-adrenergic receptors. Cardiovascular Drugs and Therapy 1999 Apr;13(2):123-6.
22. Кукес В.Г., Остроумова О.Д., Мамаев В.И., Ватутина А.М., Абакумов Ю.Е., Зыкова А.А. Эффективность и безопасность различных -блокаторов у пациентов с изолированной систолической гипертонией и сопутствующими сахарным диабетом и обструктивными болезнями легких. Терапевтический архив 2003;75(8):43-7.
23. Fogari R, Zoppi A, Tettamanti F, Poletti L, Lazzari P, Pasotti C, Corradi L. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. Journal of Cardiovascular Pharmacology 1990;16(Suppl 5):S76-80.
24. Brodde O. The pharmacology of bisoprolol. Reviews in Contemporary Pharmacotherapy 1997;8:21-33.
25. Cruickshank JM, Prichard BNC. Beta-blockers in clinical practice. 2nd ed. Edinburgh: Churchill Livingstone; 1994: 1119-26.
26. Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006;106(4):199-206.
27. Yang T, Jiang Y, Hao Y, Zhou S, Xu X, Qu B, Lin X, Ma T. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertension Research 2017 Jan;40(1):79-86.
28. Weiss RJ, Rauscher A, Shaw D. Effect of bisoprolol and atenolol on left ventricular mass in patients with essential hypertension. American Journal of Therapeutics 1994 Jun;1(1):81-5.
29. Карпов Ю.А., Шубина А.Т. -блокаторы сегодня: на передовых рубежах в борьбе с сердечно-сосудистыми заболеваниями. Русский медицинский журнал 2004;12(15):901-4.
30. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. ESC Scientific Document Group; 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018;39(33):3021-104.
31. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – overview and meta-analyses. Journal of Hypertension 2015 Feb;33(2):195-211.
32. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. British Medical Journal (Clinical Research ed.) 1985 Jul;291(6488):97-104.
33. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. Journal of Hypertension 1985 Aug;3(4):379-92.
34. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, Elmfeldt D, Jastrup B, Karatzas NB, Leer J. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991 Apr;17(4):579-88.
35. Tarnow J, M@üller RK. Cardiovascular effect of low-dose epinephrine infusions in relation to the extent of preoperative beta-adrenoceptor blockade. Anesthesiology 1991 Jun;74(6):1035-43.
36. Cruickshank JM. Don’t beta blockers still have a role in hypertension? BMJ 2011 Oct;343:d6495; author reply d6506.
37. Poulter NR, Dobson JE, Sever PS, Dahl@öf B, Wedel H, Campbell NR; ASCOT Investigators. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). Journal of American College of Cardiology 2009 Sep;54(13):1154-61.
38. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trandolapril STudy (INVEST). European Heart Journal 2008 May;29(10):1327-34.
39. Chen Y, Yang X, Nguyen Pham V, Huang S, Fu G, Chen X, Quang Truong B, Yang Y, Liu S, Chen X, Ma T, Kim DS, Kim TH. Heart rate control is associated with reduced cardiovascular events in Asian patients with coronary artery disease treated with bisoprolol (BISO-CAD): results from a multi-national, real-world experience. Current Medical Research and Opinion 2018 Feb;34(2):217-25.

References
1. Palatini P, Rosei EA, Casiglia E, Chalmers J, Ferrari R, Grassi G, Inoue T, Jelakovic B, Jensen MT, Julius S, Kjeldsen SE, Mancia G, Parati G, Pauletto P, Stella A, Zanchetti A. Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension. Journal of Hypertension 2016 May;34(5):813-21.
2. Grassi G. Sympathetic overdrive in hypertension: clinical and therapeutic relevance. An article from the e-journal of the ESC Council for Cardiology Practice. 24 Nov 2015;13(36).
3. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circulation Research 2014 May;114(11):1804-14.
4. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circulation Research 2015 Mar;116(6):976-90.
5. Cruickshank JM. Diabetes and the younger/middle-aged hypertensive subject; obesity, sympathetic nerve activity and treatment implications. Journal of Diabetes Research and Therapy 2016 Nov;3(1).
6. Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. Journal of the American Society of Hypertension 2016 May;10(5):457-66.
7. Park CS, Lee HY. Clinical utility of sympathetic blockade in cardiovascular disease management. Expert Review of Cardiovascular Therapy 2017 Mar;15(4):277-88.
8. Shubina AT, Demidova IYu, Karpov YuA. Effect of metformin on blood pressure in patients with metabolic syndrome X. International Medical Journal 2001;1:33-5 (In Russian).
9. Kobalava ZhD, Kotovskaya YuV. Features of diurnal blood pressure in hypertensive patients with metabolic disorders. Clinical Pharmacology and Therapy 1995;4(3):50-1 (In Russian).
10. Neilsen FS, Hansen HP, Jacobsen P, Rossing P, Smidt UM, Christensen NJ, Pevet P, Vivien-Roels B, Parving HH. Increased sympathetic activity during sleep and nocturnal hypertension in type 2 diabetic patients with diabetic nephropathy. Diabetic Medicine 1999 Jul;16(7):555-62.
11. Farinaro E, Stranges S, Guglielmucci G, Iermano P, Celentano E, Cajafa A, Trevisan M. Heart rate as a risk factor in hypertensive individuals. The Italian TensioPulse Study. Nutrition, Metabolism and Cardiovascular Diseases 1999 Aug;9(4):196-202.
12. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlöf B, Edelman JM, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. European Heart Journal 2010 Sep;31(18):2271-9.
13. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. The American Journal of Cardiology 2012 Mar;109(5):685-92.
14. Palatini P, Reboldi G, Beilin LJ, Eguchi K, Imai Y, Kario K, Ohkubo T, Pierdomenico SD, Saladini F, Schwartz JE, Wing L, Verdecchia P. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. International Journal of Cardiology 2013;168(2):1490-5.
15. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympatoadrenal system. The New England Journal of Medicine 1996 Feb;334(6):374-81.
16. Shubina AT, Demidova IYu, Karpov YuA. Metabolic syndrome X: background to the development of hypertension and atherosclerosis. Clinical Pharmacology and Therapy 2001;10(4):44-7 (In Russian).
17. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circulation Research 2015 Mar;116(6):976-90.
18. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Current Opinion in Nephrology and Hypertension 2012;21(1):46-51.
19. Karpov YuA, Shubina AT. β-blockers in treatment of patients with arterial hypertension: new opportunities and prospects. Russkiy Meditsinskiy Zhurnal 2005;13(19):1265-9 (In Russian).
20. Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta-adrenoceptor antagonists in vitro. Journal of Cardiovascular Pharmacology 1986;8(Suppl 11):S36-40.
21. Smith C, Teitler M. Beta-blocker selectivity at cloned human beta1- and beta2-adrenergic receptors. Cardiovascular Drugs and Therapy 1999 Apr;13(2):123-6.
22. Kukes VG, Ostroumova OD, Mamaev VI, Vatutina AM, Abakumov YuE, Zykova AA. Efficacy and safety of different -blockers in patients with isolated systolic hypertension, associated with diabetes mellitus and obstructive pulmonary diseases. Therapeutic Archive 2003;75(8):43-7 (In Russian).
23. Fogari R, Zoppi A, Tettamanti F, Poletti L, Lazzari P, Pasotti C, Corradi L. Beta-blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. Journal of Cardiovascular Pharmacology 1990;16(Suppl 5):S76-80.
24. Brodde O. The pharmacology of bisoprolol. Reviews in Contemporary Pharmacotherapy 1997;8:21-33.
25. Cruickshank JM, Prichard BNC. Beta-blockers in clinical practice. 2nd ed. Edinburgh: Churchill Livingstone; 1994: 1119-26.
26. Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology 2006;106(4):199-206.
27. Yang T, Jiang Y, Hao Y, Zhou S, Xu X, Qu B, Lin X, Ma T. Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertension Research 2017 Jan;40(1):79-86.
28. Weiss RJ, Rauscher A, Shaw D. Effect of bisoprolol and atenolol on left ventricular mass in patients with essential hypertension. American Journal of Therapeutics 1994 Jun;1(1):81-5.
29. Karpov YuA, Shubina AT. -blockers today: at the forefront in fight against cardiovascular diseases. Russkiy Meditsinskiy Zhurnal 2004;12(15):901-4 (In Russian).
30. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; ESC Scientific Document Group. ESC Scientific Document Group; 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal 2018;39(33):3021-104.
31. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – overview and meta-analyses. Journal of Hypertension 2015 Feb;33(2):195-211.
32. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. British Medical Journal (Clinical Research ed.) 1985 Jul;291(6488):97-104.
33. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. Journal of Hypertension 1985 Aug;3(4):379-92.
34. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, Elmfeldt D, Jastrup B, Karatzas NB, Leer J. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991 Apr;17(4):579-88.
35. Tarnow J, Müller RK. Cardiovascular effect of low-dose epinephrine infusions in relation to the extent of preoperative beta-adrenoceptor blockade. Anesthesiology 1991 Jun;74(6):1035-43.
36. Cruickshank JM. Don’t beta blockers still have a role in hypertension? BMJ 2011 Oct;343:d6495; author reply d6506.
37. Poulter NR, Dobson JE, Sever PS, Dahlöf B, Wedel H, Campbell NR; ASCOT Investigators. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). Journal of American College of Cardiology 2009 Sep;54(13):1154-61.
38. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trandolapril STudy (INVEST). European Heart Journal 2008 May;29(10):1327-34.
39. Chen Y, Yang X, Nguyen Pham V, Huang S, Fu G, Chen X, Quang Truong B, Yang Y, Liu S, Chen X, Ma T, Kim DS, Kim TH. Heart rate control is associated with reduced cardiovascular events in Asian patients with coronary artery disease treated with bisoprolol (BISO-CAD): results from a multi-national, real-world experience. Current Medical Research and Opinion 2018 Feb;34(2):217-25.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]